Treatment of advanced hepatocellular carcinoma: Intraarterial infusion chemotherapy combined with interferon

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 142-147

  Nagano, Hiroaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Chemotherapy; Fluorouracil arterial infusion and IFN therapy; Hepatocellular carcinoma; IFN therapy; Interferon; Intraarterial infusion; Portal venous tumor thrombus

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CHILL; DEPRESSION; DIARRHEA; DRUG POTENTIATION; DRUG SENSITIVITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER RESECTION; MUCOSA INFLAMMATION; NAUSEA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMACH ULCER; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERONS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 77954517851     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315243     Document Type: Review

References (30)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Kiyosawa K, Umemura T, Ichijo T, et al: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127:S17-S26.
3. Doci R, Bignami P, Bozzetti F, et al: Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988; 61: 1983-1987.
4. Stehlin JS Jr, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR, McNary L: Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1988; 208: 23-35.
5. The Gastrointestinal Tumor Study Group: A prospective trial of recombinant human IFN- 2b in previously untreated patients with hepatocellular carcinoma. Cancer 1990; 66: 135-139.
6. Yuen MF, Ooi CG, Hui CK, et al: A pilot study of transcatheter arterial IFN embolization for patients with hepatocellular carcinoma. Cancer 2003; 97: 2776-2782.
7. Lai CL, Lau JY, Wu PC, et al: Recombinant IFN- in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389-394.
8. Llovet JM, Sala M, Castells L, et al: Randomized controlled trial of IFN treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-58.
9. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant IFN-2 b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21: 421-427.
10. Miyamoto A, Umeshita K, Sakon M, et al: Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of-IFN and oral tegafur/ uracil. J Gastroenterol Hepatol 2000; 15: 1447-1451.
11. Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous IFN- therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442.
12. Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous IFN- and intraarterial 5-fluorouracil; role of type 1 IFN receptor expression. Br J Cancer 2005; 93: 557-564.
13. Enjoji M, Morizono S, Kotoh K, et al: Reevaluation of antitumor effects of combination chemotherapy with IFN- and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5685-5687.
14. Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic IFN- for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997.
15. Poon RT, Fan ST, Ng IO, Wong J: Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003; 237: 376-383.
16. Nagano H, Sakon M, Eguchi H, et al: Hepatic resection followed by IFN- and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2007; 54: 172-179.
17. Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603.
18. Damdinsuren B, Nagano H, Sakon M, et al: IFN- is more potent than IFN- in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003; 10: 1184-1190.
19. Eguchi H, Nagano H, Yamamoto H, et al: Augmentation of antitumor activity of 5-fluorouracil by IFN- is associated with upregulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881-2890.
20. Kondo M, Nagano H, Wada H, et al: Combination of IFN- and 5-fluorouracil induces apoptosis through IFN- /receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 1277-1286.
21. Ota H, Nagano H, Doki Y, et al: Expression of type I IFN receptor as a predictor of clinical response to IFN- therapy of gastrointestinal cancers. Oncol Rep 2006; 16: 249-255.
22. Damdinsuren B, Nagano H, Wada H, et al: Stronger growth-inhibitory effect of IFN- compared to IFN- is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol 2007; 30: 201-208.
23. Damdinsuren B, Nagano H, Wada H, et al: IFN- receptors are important for antiproliferative effect of IFN- against human hepatocellular carcinoma cells. Hepatol Res 2007; 37: 77-83.
24. Nagano H, Miyamoto A, Wada H, et al: IFN- and 5-fluorouracil combination therapy following palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk and multiple nodules. Cancer 2007; 110: 2493-2501.
25. Yamamoto T, Nagano H, Sakon M, et al: Partial contribution of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)/ TRAIL receptor pathway to antitumor effects of IFN- /5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7884-7895.
26. Nakamura M, Nagano H, Sakon M, et al: Role of the Fas/FasL pathway in combination therapy with IFN- and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007; 46: 77-88.
27. Wada H, Nagano H, Yamamoto H, et al: Combination therapy of IFN- and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 2007; 18: 801-809.
28. Takaoka A, Hayakawa S, Yanai H, et al: Integration of IFN- /signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523.
29. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
30. Kurokawa Y, Matoba R, Nagano H, et al: Molecular prediction of response to 5-fluorouracil and IFN- combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10: 6029-6038.